drugset
drugset / Trial / NCT04249843

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

NCT04249843 ↗

Phase 1 Terminated 109 enrolled MapKure, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors

Timeline

Start
2020-02-17
Primary completion
2025-08-04
Completion
2025-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BGB-3245 Unknown — Oral

Indications

cancer